Evidence map›Paper›PMID 33924340›Full record

ArticleVaccines2021

Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST).

Madhusudhanan Narasimhan, Lenin Mahimainathan, Ellen Araj, Andrew E Clark, Kathleen Wilkinson, Sruthi Yekkaluri, Jasmin Tiro, Francesca M Lee, Jyoti Balani, Ravi Sarode and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Madhusudhanan NarasimhanDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lenin MahimainathanDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ellen ArajDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Andrew E ClarkDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Kathleen WilkinsonDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Sruthi YekkaluriDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jasmin TiroDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Francesca M LeeDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jyoti BalaniDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ravi SarodeDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Amit G SingalDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Alagarraju MuthukumarDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Funding

The State of Texas, Tarrant County, Dallas County, the City of Fort Worth, and the City of Dallas, private philanthropy including Lyda Hill Philanthropies and W.W. Caruth, Jr. Fund at Communities Foundation of Texas
6 · The paper itself

Abstract

backgroundThe persisting Coronavirus disease 2019 (COVID-19) pandemic and limited vaccine supply has led to a shift in global health priorities to expand vaccine coverage. Relying on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) molecular testing alone cannot reveal the infection proportion, which could play a critical role in vaccination prioritization. We evaluated the utility of a combination orthogonal serological testing (COST) algorithm alongside RT-PCR to quantify prevalence with the aim of identifying candidate patient clusters to receive single and/or delayed vaccination.

methodsWe utilized 108,505 patients with suspected COVID-19 in a retrospective analysis of SARS-CoV-2 RT-PCR vs. IgG-nucleocapsid (IgG

resultsRetrospectively, we observed a 6.3% (6871/108,505) positivity for SARS-CoV-2 RT-PCR, and only 2.3% (2533/108,505) of cases had paired IgG

conclusionCOST may be an effective tool for the evaluation of infection proportion and thus could define a cohort for a single dose and/or delayed vaccination.

Indexed as

COVID-19IgGIgMnucleocapsidorthogonal antibody testingSARS-CoV-2spikevaccinevaccine prioritization

Identifiers

PMID33924340
PMCPMC8069830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.